JPMorgan offers leveraged barrier notes tied to NVO and CPNG

Rhea-AI Filing Summary

JPMorgan Chase Financial Company LLC is offering uncapped accelerated barrier notes linked to the lesser performing of ADRs of Novo Nordisk A/S and Class A common stock of Coupang, Inc. The notes (minimum denomination $1,000) are designed to provide an upside leverage factor of at least 3.9375 on any appreciation of the lesser performing Reference Stock at maturity and a Barrier Amount equal to 75.00% of each Reference Stock's Strike Value.

Key economics: Strike Values were set by reference to closing prices on June 10, 2026 (NVO $42.81, CPNG $15.12); Pricing Date is on or about June 11, 2026; Settlement on or about June 16, 2026; Observation Date June 11, 2029; Maturity Date June 14, 2029. Payments at maturity depend on the Lesser Performing Stock Return and may result in full loss of principal if the Final Value falls below the Barrier Amount.

Insights

Structured Products Strategist

Notes provide leveraged upside on the lesser performing stock with a hard downside barrier at 75% of strike.

The structure uses an Upside Leverage Factor of at least 3.9375 applied to the Lesser Performing Stock Return to calculate upside payoff; if both Final Values exceed their strikes, investors receive principal plus leveraged return. If either Final Value is below the Barrier Amount (75.00% of strike), holders are exposed to linear downside tied to the Lesser Performing Stock Return.

Dependencies and risks include the issuer/guarantor credit and the specific Strike Values set on June 10, 2026. Secondary market liquidity and the estimated value floor (not less than $940.00 per $1,000 when set) are relevant for pricing and potential early sales.

Credit & Market Risk Analyst

Credit exposure to JPMorgan Financial and JPMorgan Chase & Co. is a primary valuation driver.

The notes are unsecured obligations of JPMorgan Financial and are fully and unconditionally guaranteed by JPMorgan Chase & Co., making investor recovery dependent on both entities' creditworthiness. The pricing supplement emphasizes credit‑risk sensitivity and potential acceleration events that could shorten term and affect payout determinations.

Also note model and secondary‑market risks: the estimated value is derived using an internal funding rate and derivative models; secondary prices will likely be lower than original issue price and liquidity is limited because notes are unlisted.

Key Figures

Upside Leverage Factor: 3.9375 Barrier Amount: 75.00% of Strike Value Strike Value (NVO): $42.81 +5 more

8 metrics

Upside Leverage Factor 3.9375 stated minimum Upside Leverage Factor

Barrier Amount 75.00% of Strike Value applies to each Reference Stock

Strike Value (NVO) $42.81 closing price on June 10, 2026

Strike Value (CPNG) $15.12 closing price on June 10, 2026

Estimated value (example) $960.00 per $1,000 illustrative estimated value if notes priced today

Minimum estimated value floor $940.00 per $1,000 stated guaranteed floor when terms are set

Observation Date June 11, 2029 date used to determine Final Values

Maturity Date June 14, 2029 scheduled maturity

Key Terms

ADR, Upside Leverage Factor, Barrier Amount, Estimated value, +1 more

5 terms

ADR financial

"American depositary receipts (“ADRs”), each representing one B share"

An American Depositary Receipt (ADR) is a financial certificate that lets investors buy shares of a foreign company through U.S. stock markets, similar to buying a local wrapper that represents the underlying foreign shares. ADRs matter because they make investing in overseas companies easier and more liquid by trading in U.S. dollars and under U.S. market rules, while still carrying currency, regulatory, and country-specific risks that can affect share value.

Upside Leverage Factor financial

"Upside Leverage Factor: At least 3.9375 (to be provided in the pricing supplement)"

Barrier Amount financial

"Barrier Amount: With respect to each Reference Stock, 75.00% of its Strike Value"

Estimated value financial

"If the notes priced today, the estimated value of the notes would be approximately $960.00"

Section 871(m) regulatory

"Section 871(m) of the Code and Treasury regulations promulgated thereunder"

A U.S. tax rule that treats certain payments from financial contracts (like options, swaps, and other instruments that mimic stock dividends) to non-U.S. investors as if they were direct dividends, requiring U.S. withholding tax. It matters to investors because it can reduce net returns on offshore trades that replicate U.S. equity income and may change pricing or counterparty behavior—think of it as a hidden sales tax that applies when a substitute payment acts like a dividend.

Offering Details

primary

Offering

Offering Type primary

Use of Proceeds proceeds reflect estimated value plus selling commissions and projected hedging profits/losses

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What payoff does JPM's note (JPM) offer at maturity?

The notes pay $1,000 plus leveraged return when both Reference Stocks finish above their strikes. If both Final Values exceed strikes, the payoff equals $1,000 + ($1,000 × Lesser Performing Stock Return × 3.9375). If either Final Value is at or below its strike but above the Barrier, you get principal.

How can I lose principal on these JPMorgan notes (JPM)?

You can lose up to all principal if either Reference Stock falls below its Barrier Amount. If the Final Value of either Reference Stock is below 75.00% of its Strike Value, your payment equals $1,000 + ($1,000 × Lesser Performing Stock Return), potentially producing total loss.

What are the key dates and Strike Values for the offering?

Strike Values were set by the closing prices on June 10, 2026; Pricing Date ~June 11, 2026; Settlement ~June 16, 2026; Maturity June 14, 2029. Strikes: NVO $42.81 and CPNG $15.12.

What is the estimated value and how does it compare to the issue price?

The estimated value at pricing was approximately $960.00 per $1,000; it will not be less than $940.00. The original issue price exceeds the estimated value due to selling commissions, projected hedging profits, and structuring costs included in the price.

Are these notes protected by FDIC insurance or exchange listing?

No. These notes are not bank deposits and are not FDIC insured. They will not be listed on any securities exchange and secondary market liquidity is limited, depending on JPMS willingness to buy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 11:22 AM Learn about SEC filing dates

The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not
an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject to completion dated June 11, 2026
June , 2026 Registration Statement Nos. 333-293684 and 333-293684-01; Rule 424(b)(2)
Pricing supplement to product supplement no. 3-I dated April 17, 2026 and the prospectus and prospectus supplement, each dated April 17, 2026
JPMorgan Chase Financial Company LLC
Structured Investments
Uncapped Accelerated Barrier Notes Linked to the Lesser
Performing of the American Depositary Receipts of Novo
Nordisk A/S and the Class A Common Stock of Coupang,
Inc. due June 14, 2029
Fully and Unconditionally Guaranteed by JPMorgan Chase & Co.
• The notes are designed for investors who seek an uncapped return of at least 3.9375 times any appreciation of the
lesser performing of the Reference Stocks at maturity.
• Investors should be willing to forgo interest and dividend payments and be willing to lose a significant portion or all of
their principal amount at maturity.
• The notes are unsecured and unsubordinated obligations of JPMorgan Chase Financial Company LLC, which we refer to
as JPMorgan Financial, the payment on which is fully and unconditionally guaranteed by JPMorgan Chase & Co. Any
payment on the notes is subject to the credit risk of JPMorgan Financial, as issuer of the notes, and the credit
risk of JPMorgan Chase & Co., as guarantor of the notes.
• Payments on the notes are not linked to a basket composed of the Reference Stocks. Payments on the notes are linked
to the performance of each of the Reference Stocks individually, as described below.
• Minimum denominations of $1,000 and integral multiples thereof
• The notes are expected to price on or about June 11, 2026 (the “Pricing Date”) and are expected to settle on or about
June 16, 2026. The Strike Value of each Reference Stock has been determined by reference to the closing price
of one share of that Reference Stock on June 10, 2026 and not by reference to the closing price of one share of
that Reference Stock on the Pricing Date.
• CUSIP: 46661AZW3
Investing in the notes involves a number of risks. See “Risk Factors” beginning on page S-2 of the accompanying
prospectus supplement, “Risk Factors” beginning on page PS-12 of the accompanying product supplement and
“Selected Risk Considerations” beginning on page PS-4 of this pricing supplement.
Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved
of the notes or passed upon the accuracy or the adequacy of this pricing supplement or the accompanying product supplement,
prospectus supplement and prospectus. Any representation to the contrary is a criminal offense.
Price to Public (1)(2)
Fees and Commissions (2)(3)
Proceeds to Issuer
Per note
$1,000
$
$
Total
$
$
$
(1) See “Supplemental Use of Proceeds” in this pricing supplement for information about the components of the price to public of the
notes.
(2) With respect to notes sold to certain fee-based advisory accounts for which an affiliated or unaffiliated broker-dealer is an
investment adviser, the price to the public will not be lower than $971.50 per $1,000 principal amount note. J.P. Morgan Securities
LLC, which we refer to as JPMS, and these broker-dealers will forgo any selling commissions related to these sales. See “Plan of
Distribution (Conflicts of Interest)” in the accompanying product supplement.
(3) With respect to notes sold to brokerage accounts, JPMS, acting as agent for JPMorgan Financial, will pay all of the selling
commissions it receives from us to other affiliated or unaffiliated dealers. In no event will these selling commissions exceed $28.50 per
$1,000 principal amount note. See “Plan of Distribution (Conflicts of Interest)” in the accompanying product supplement.
If the notes priced today, the estimated value of the notes would be approximately $960.00 per $1,000 principal amount
note. The estimated value of the notes, when the terms of the notes are set, will be provided in the pricing supplement
and will not be less than $940.00 per $1,000 principal amount note. See “The Estimated Value of the Notes” in this
pricing supplement for additional information.
The notes are not bank deposits, are not insured by the Federal Deposit Insurance Corporation or any other governmental agency
and are not obligations of, or guaranteed by, a bank.

PS-1 | Structured Investments
Uncapped Accelerated Barrier Notes Linked to the Lesser Performing of the
American Depositary Receipts of Novo Nordisk A/S and the Class A
Common Stock of Coupang, Inc.
Key Terms
Issuer: JPMorgan Chase Financial Company LLC, a direct,
wholly owned finance subsidiary of JPMorgan Chase & Co.
Guarantor: JPMorgan Chase & Co.
Reference Stocks: As specified under “Key Terms Relating to
the Reference Stocks” in this pricing supplement
Upside Leverage Factor: At least 3.9375 (to be provided in the
pricing supplement)
Barrier Amount: With respect to each Reference Stock,
75.00% of its Strike Value, as specified under “Key Terms
Relating to the Reference Stocks” in this pricing supplement
Strike Date: June 10, 2026
Pricing Date: On or about June 11, 2026
Original Issue Date (Settlement Date): On or about June 16,
2026
Observation Date*: June 11, 2029
Maturity Date*: June 14, 2029
* Subject to postponement in the event of a market disruption event
and as described under “General Terms of Notes — Postponement
of a Determination Date — Notes Linked to Multiple Underlyings”
and “General Terms of Notes — Postponement of a Payment Date”
in the accompanying product supplement or early acceleration in
the event of an acceleration event as described under “General
Terms of Notes — Consequences of an Acceleration Event” in the
accompanying product supplement and “Selected Risk
Considerations — Risks Relating to the Notes Generally — We May
Accelerate Your Notes If an Acceleration Event Occurs” in this
pricing supplement
Payment at Maturity:
If the Final Value of each Reference Stock is greater than its
Strike Value, your payment at maturity per $1,000 principal
amount note will be calculated as follows:
$1,000 + ($1,000 × Lesser Performing Stock Return × Upside
Leverage Factor)
If the Final Value of either Reference Stock is equal to or less
than its Strike Value but the Final Value of each Reference
Stock is greater than or equal to its Barrier Amount, you will
receive the principal amount of your notes at maturity.
If the Final Value of either Reference Stock is less than its
Barrier Amount, your payment at maturity per $1,000 principal
amount note will be calculated as follows:
$1,000 + ($1,000 × Lesser Performing Stock Return)
If the Final Value of either Reference Stock is less than its
Barrier Amount, you will lose more than 25.00% of your
principal amount at maturity and could lose all of your principal
amount at maturity.
Lesser Performing Reference Stock: The Reference Stock
with the Lesser Performing Stock Return
Lesser Performing Stock Return: The lower of the Stock
Returns of the Reference Stocks
Stock Return:
With respect to each Reference Stock,
(Final Value – Strike Value)
Strike Value
Strike Value: With respect to each Reference Stock, the
closing price of one share of that Reference Stock on the Strike
Date, as specified under “Key Terms Relating to the Reference
Stocks” in this pricing supplement. The Strike Value of each
Reference Stock is not the closing price of one share of
that Reference Stock on the Pricing Date.
Final Value: With respect to each Reference Stock, the closing
price of one share of that Reference Stock on the Observation
Date
Stock Adjustment Factor: With respect to each Reference
Stock, the Stock Adjustment Factor is referenced in determining
the closing price of one share of that Reference Stock and is set
equal to 1.0 on the Strike Date. The Stock Adjustment Factor of
each Reference Stock is subject to adjustment upon the
occurrence of certain corporate events affecting that Reference
Stock. See “The Underlyings — Reference Stocks — Anti-
Dilution Adjustments” and “The Underlyings — Reference
Stocks — Reorganization Events” in the accompanying product
supplement for further information.

PS-2 | Structured Investments
Uncapped Accelerated Barrier Notes Linked to the Lesser Performing of the
American Depositary Receipts of Novo Nordisk A/S and the Class A
Common Stock of Coupang, Inc.
Key Terms Relating to the Reference Stocks
Reference Stock
Bloomberg Ticker Symbol
Strike Value
Barrier Amount
American depositary receipts (“ADRs”), each representing one B
share, nominal value DKK 0.10 each, of Novo Nordisk A/S
NVO
$42.81
$32.1075
Class A common stock of Coupang, Inc., par value $0.0001 per
share
CPNG
$15.12
$11.34

PS-3 | Structured Investments
Uncapped Accelerated Barrier Notes Linked to the Lesser Performing of the
American Depositary Receipts of Novo Nordisk A/S and the Class A
Common Stock of Coupang, Inc.
Hypothetical Payout Profile
The following table and graph illustrate the hypothetical total return and payment at maturity on the notes linked to two hypothetical
Reference Stocks. The “total return” as used in this pricing supplement is the number, expressed as a percentage, that results from
comparing the payment at maturity per $1,000 principal amount note to $1,000. The hypothetical total returns and payments set forth
below assume the following:
• the notes were sold only to brokerage accounts;
• a Strike Value for the Lesser Performing Reference Stock of $100.00;
• an Upside Leverage Factor of 3.9375; and
• a Barrier Amount for the Lesser Performing Reference Stock of 75.00 (equal to 75.00% of its hypothetical Strike Value).
The hypothetical Strike Value of the Lesser Performing Reference Stock of $100.00 has been chosen for illustrative purposes only and
does not represent the actual Strike Value of either Reference Stock. The actual Strike Value of each Reference Stock is the closing
price of one share of that Reference Stock on the Strike Date and is specified under “Key Terms Relating to the Reference Stocks” in
this pricing supplement. For historical data regarding the actual closing prices of one share of each Reference Stock, please see the
historical information set forth under “The Reference Stocks” in this pricing supplement.
Each hypothetical total return or hypothetical payment at maturity set forth below is for illustrative purposes only and may not be the
actual total return or payment at maturity applicable to a purchaser of the notes. The numbers appearing in the following table and
graph have been rounded for ease of analysis.
Final Value of the
Lesser Performing
Reference Stock
Lesser Performing Stock
Return
Total Return on the Notes
Payment at Maturity
$165.00
65.00%
255.9375%
$3,559.375
$150.00
50.00%
196.8750%
$2,968.750
$140.00
40.00%
157.5000%
$2,575.000
$130.00
30.00%
118.1250%
$2,181.250
$120.00
20.00%
78.7500%
$1,787.500
$110.00
10.00%
39.3750%
$1,393.750
$105.00
5.00%
19.6875%
$1,196.875
$101.00
1.00%
3.9375%
$1,039.375
$100.00
0.00%
0.0000%
$1,000.000
$95.00
-5.00%
0.0000%
$1,000.000
$90.00
-10.00%
0.0000%
$1,000.000
$80.00
-20.00%
0.0000%
$1,000.000
$75.00
-25.00%
0.0000%
$1,000.000
$74.99
-25.01%
-25.0100%
$749.900
$70.00
-30.00%
-30.0000%
$700.000
$60.00
-40.00%
-40.0000%
$600.000
$50.00
-50.00%
-50.0000%
$500.000
$40.00
-60.00%
-60.0000%
$400.000
$30.00
-70.00%
-70.0000%
$300.000
$20.00
-80.00%
-80.0000%
$200.000
$10.00
-90.00%
-90.0000%
$100.000
$0.00
-100.00%
-100.0000%
$0.000

PS-4 | Structured Investments
Uncapped Accelerated Barrier Notes Linked to the Lesser Performing of the
American Depositary Receipts of Novo Nordisk A/S and the Class A
Common Stock of Coupang, Inc.
The following graph demonstrates the hypothetical payments at maturity on the notes for a range of Lesser Performing Stock Returns.
There can be no assurance that the performance of the Lesser Performing Reference Stock will result in the return of any of your
principal amount.
How the Notes Work
Upside Scenario:
If the Final Value of each Reference Stock is greater than its Strike Value, investors will receive at maturity the $1,000 principal amount
plus a return equal to the Lesser Performing Stock Return times the Upside Leverage Factor of at least 3.9375.
• Assuming a hypothetical Upside Leverage Factor of 3.9375, if the closing price of one share of the Lesser Performing Reference
Stock increases 10.00%, investors will receive at maturity a return equal to 39.375%, or $1,393.75 per $1,000 principal amount
note.
Par Scenario:
If the Final Value of either Reference Stock is equal to or less than its Strike Value but the Final Value of each Reference Stock is
greater than or equal to its Barrier Amount of 75.00% of its Strike Value, investors will receive at maturity the principal amount of their
notes.
Downside Scenario:
If the Final Value of either Reference Stock is less than its Barrier Amount of 75.00% of its Strike Value, investors will lose 1% of the
principal amount of their notes for every 1% that the Final Value of the Lesser Performing Reference Stock is less than its Strike Value.
• For example, if the closing price of one share of the Lesser Performing Reference Stock declines 60.00%, investors will lose
60.00% of their principal amount and receive only $400.00 per $1,000 principal amount note at maturity.
The hypothetical returns and hypothetical payments on the notes shown above apply only if you hold the notes for their entire term.
These hypotheticals do not reflect the fees or expenses that would be associated with any sale in the secondary market. If these fees
and expenses were included, the hypothetical returns and hypothetical payments shown above would likely be lower.
Selected Risk Considerations
An investment in the notes involves significant risks. These risks are explained in more detail in the “Risk Factors” sections of the
accompanying prospectus supplement and product supplement.
Risks Relating to the Notes Generally
• YOUR INVESTMENT IN THE NOTES MAY RESULT IN A LOSS —
The notes do not guarantee any return of principal. If the Final Value of either Reference Stock is less than its Barrier Amount, you
will lose 1% of the principal amount of your notes for every 1% that the Final Value of the Lesser Performing Reference Stock is

PS-5 | Structured Investments
Uncapped Accelerated Barrier Notes Linked to the Lesser Performing of the
American Depositary Receipts of Novo Nordisk A/S and the Class A
Common Stock of Coupang, Inc.
less than its Strike Value. Accordingly, under these circumstances, you will lose more than 25.00% of your principal amount at
maturity and could lose all of your principal amount at maturity.
• CREDIT RISKS OF JPMORGAN FINANCIAL AND JPMORGAN CHASE & CO. —
Investors are dependent on our and JPMorgan Chase & Co.’s ability to pay all amounts due on the notes. Any actual or potential
change in our or JPMorgan Chase & Co.’s creditworthiness or credit spreads, as determined by the market for taking that credit
risk, is likely to adversely affect the value of the notes. If we and JPMorgan Chase & Co. were to default on our payment
obligations, you may not receive any amounts owed to you under the notes and you could lose your entire investment.
• AS A FINANCE SUBSIDIARY, JPMORGAN FINANCIAL HAS NO INDEPENDENT ACTIVITIES AND HAS LIMITED ASSETS —
As a finance subsidiary of JPMorgan Chase & Co., we have no independent activities beyond the issuance and administration of
our securities and the collection of intercompany obligations. Aside from the initial capital contribution from JPMorgan Chase &
Co., substantially all of our assets relate to obligations of JPMorgan Chase & Co. to make payments under loans made by us to
JPMorgan Chase & Co. or under other intercompany agreements. As a result, we are dependent upon payments from JPMorgan
Chase & Co. to meet our obligations under the notes. We are not an operating subsidiary of JPMorgan Chase & Co. and in a
bankruptcy or resolution of JPMorgan Chase & Co. we are not expected to have sufficient resources to meet our obligations in
respect of the notes as they come due. If JPMorgan Chase & Co. does not make payments to us and we are unable to make
payments on the notes, you may have to seek payment under the related guarantee by JPMorgan Chase & Co., and that
guarantee will rank pari passu with all other unsecured and unsubordinated obligations of JPMorgan Chase & Co. For more
information, see “Risk Factors — Holders of securities issued by JPMorgan Financial may be subject to losses if JPMorgan Chase
& Co. were to enter into a resolution” in the accompanying prospectus supplement.
• YOU ARE EXPOSED TO THE RISK OF DECLINE IN THE PRICE OF ONE SHARE OF EACH REFERENCE STOCK —
Payments on the notes are not linked to a basket composed of the Reference Stocks and are contingent upon the performance of
each individual Reference Stock. Poor performance by either of the Reference Stocks over the term of the notes may negatively
affect your payment at maturity and will not be offset or mitigated by positive performance by the other Reference Stock.
• YOUR PAYMENT AT MATURITY WILL BE DETERMINED BY THE LESSER PERFORMING REFERENCE STOCK.
• THE BENEFIT PROVIDED BY THE BARRIER AMOUNT MAY TERMINATE ON THE OBSERVATION DATE —
If the Final Value of either Reference Stock is less than its Barrier Amount, the benefit provided by the Barrier Amount will
terminate and you will be fully exposed to any depreciation of the Lesser Performing Reference Stock.
• THE NOTES DO NOT PAY INTEREST.
• YOU WILL NOT RECEIVE DIVIDENDS ON EITHER REFERENCE STOCK OR HAVE ANY RIGHTS WITH RESPECT TO
EITHER REFERENCE STOCK.
• THE RISK OF THE CLOSING PRICE OF ONE SHARE OF A REFERENCE STOCK FALLING BELOW ITS BARRIER AMOUNT
IS GREATER IF THE PRICE OF ONE SHARE OF THAT REFERENCE STOCK IS VOLATILE.
• WE MAY ACCELERATE YOUR NOTES IF AN ACCELERATION EVENT OCCURS —
Upon the announcement or occurrence of an acceleration event, we may, in our sole and absolute discretion, accelerate the
payment on your notes and pay you an amount determined by the calculation agent in good faith and in a commercially reasonable
manner by reference to the values of any fixed-income debt component and any derivatives underlying the economic terms of the
notes as of the date of the notice of acceleration. An acceleration event means a Reference Stock (other than the ADRs of Novo
Nordisk A/S) is no longer listed or admitted to trading on its relevant exchange and the calculation agent determines, in its sole
discretion, that no Replacement Reference Stock (as defined in the accompanying product supplement) is available, or the ADRs
of Novo Nordisk A/S are no longer listed or admitted to trading on a U.S. national securities exchange registered under the
Exchange Act (as defined under “The Reference Stocks” below), or on any other U.S. national market system or quotation system
that is the primary market for the trading of the ADRs of Novo Nordisk A/S, or the ADS facility between Novo Nordisk A/S and the
ADS depositary is terminated for any reason, and the calculation agent determines, in its sole discretion, that no Replacement ADS
(as defined in the accompanying product supplement) is available and the B shares of Novo Nordisk A/S are not selected to
replace the ADRs of Novo Nordisk A/S as a Reference Stock. If the payment on your notes is accelerated, your investment may
result in a loss, and you may not be able to reinvest your money in a comparable investment. Please see “The Underlyings —
Reference Stocks — Delisting of a Reference Stock or Nationalization of a Reference Stock Issuer” and “The Underlyings —
Reference Stocks — Delisting of ADSs or Termination of ADS Facility” in the accompanying product supplement for more
information.

PS-6 | Structured Investments
Uncapped Accelerated Barrier Notes Linked to the Lesser Performing of the
American Depositary Receipts of Novo Nordisk A/S and the Class A
Common Stock of Coupang, Inc.
• LACK OF LIQUIDITY —
The notes will not be listed on any securities exchange. Accordingly, the price at which you may be able to trade your notes is
likely to depend on the price, if any, at which JPMS is willing to buy the notes. You may not be able to sell your notes. The notes
are not designed to be short-term trading instruments. Accordingly, you should be able and willing to hold your notes to maturity.
• THE FINAL TERMS AND VALUATION OF THE NOTES WILL BE PROVIDED IN THE PRICING SUPPLEMENT —
You should consider your potential investment in the notes based on the minimums for the estimated value of the notes and the
Upside Leverage Factor.
Risks Relating to Conflicts of Interest
• POTENTIAL CONFLICTS —
We and our affiliates play a variety of roles in connection with the notes. In performing these duties, our and JPMorgan Chase &
Co.’s economic interests are potentially adverse to your interests as an investor in the notes. It is possible that hedging or trading
activities of ours or our affiliates in connection with the notes could result in substantial returns for us or our affiliates while the
value of the notes declines. Please refer to “Risk Factors — Risks Relating to Conflicts of Interest” in the accompanying product
supplement.
Risks Relating to the Estimated Value and Secondary Market Prices of the Notes
• THE ESTIMATED VALUE OF THE NOTES WILL BE LOWER THAN THE ORIGINAL ISSUE PRICE (PRICE TO PUBLIC) OF
THE NOTES —
The estimated value of the notes is only an estimate determined by reference to several factors. The original issue price of the
notes will exceed the estimated value of the notes because costs associated with selling, structuring and hedging the notes are
included in the original issue price of the notes. These costs include the selling commissions, if any, the projected profits, if any,
that our affiliates expect to realize for assuming risks inherent in hedging our obligations under the notes, the estimated cost of
hedging our obligations under the notes and the fees, if any, paid for third-party data analytics and/or electronic platform services.
See “The Estimated Value of the Notes” in this pricing supplement.
• THE ESTIMATED VALUE OF THE NOTES DOES NOT REPRESENT FUTURE VALUES OF THE NOTES AND MAY DIFFER
FROM OTHERS’ ESTIMATES —
See “The Estimated Value of the Notes” in this pricing supplement.
• THE ESTIMATED VALUE OF THE NOTES IS DERIVED BY REFERENCE TO AN INTERNAL FUNDING RATE —
The internal funding rate used in the determination of the estimated value of the notes may differ from the market-implied funding
rate for vanilla fixed income instruments of a similar maturity issued by JPMorgan Chase & Co. or its affiliates. Any difference may
be based on, among other things, our and our affiliates’ view of the funding value of the notes as well as the higher issuance,
operational and ongoing liability management costs of the notes in comparison to those costs for the conventional fixed income
instruments of JPMorgan Chase & Co. This internal funding rate is based on certain market inputs and assumptions, which may
prove to be incorrect, and is intended to approximate the prevailing market replacement funding rate for the notes. The use of an
internal funding rate and any potential changes to that rate may have an adverse effect on the terms of the notes and any
secondary market prices of the notes. See “The Estimated Value of the Notes” in this pricing supplement.
• THE VALUE OF THE NOTES AS PUBLISHED BY JPMS (AND WHICH MAY BE REFLECTED ON CUSTOMER ACCOUNT
STATEMENTS) MAY BE HIGHER THAN THE THEN-CURRENT ESTIMATED VALUE OF THE NOTES FOR A LIMITED TIME
PERIOD —
We generally expect that some of the costs included in the original issue price of the notes will be partially paid back to you in
connection with any repurchases of your notes by JPMS in an amount that will decline to zero over an initial predetermined period.
See “Secondary Market Prices of the Notes” in this pricing supplement for additional information relating to this initial period.
Accordingly, the estimated value of your notes during this initial period may be lower than the value of the notes as published by
JPMS (and which may be shown on your customer account statements).
• SECONDARY MARKET PRICES OF THE NOTES WILL LIKELY BE LOWER THAN THE ORIGINAL ISSUE PRICE OF THE
NOTES —
Any secondary market prices of the notes will likely be lower than the original issue price of the notes because, among other
things, secondary market prices take into account our internal secondary market funding rates for structured debt issuances and,

PS-7 | Structured Investments
Uncapped Accelerated Barrier Notes Linked to the Lesser Performing of the
American Depositary Receipts of Novo Nordisk A/S and the Class A
Common Stock of Coupang, Inc.
also, because secondary market prices may exclude selling commissions, if any, projected hedging profits, if any, estimated
hedging costs and fees, if any, paid for third-party data analytics and/or electronic platform services that are included in the original
issue price of the notes. As a result, the price, if any, at which JPMS will be willing to buy the notes from you in secondary market
transactions, if at all, is likely to be lower than the original issue price. Furthermore, if you sell your notes, you will likely be charged
a commission for secondary market transactions, or the price will likely reflect a dealer discount and/or fees for use of an electronic
platform to facilitate secondary market activity. Any sale by you prior to the Maturity Date could result in a substantial loss to you.
• SECONDARY MARKET PRICES OF THE NOTES WILL BE IMPACTED BY MANY ECONOMIC AND MARKET FACTORS —
The secondary market price of the notes during their term will be impacted by a number of economic and market factors, which
may either offset or magnify each other, aside from the selling commissions, if any, projected hedging profits, if any, estimated
hedging costs and the prices of one share of the Reference Stocks. Additionally, independent pricing vendors and/or third party
broker-dealers may publish a price for the notes, which may also be reflected on customer account statements. This price may be
different (higher or lower) than the price of the notes, if any, at which JPMS may be willing to purchase your notes in the secondary
market. See “Risk Factors — Risks Relating to the Estimated Value and Secondary Market Prices of the Notes — Secondary
market prices of the notes will be impacted by many economic and market factors” in the accompanying product supplement.
Risks Relating to the Reference Stocks
• NO AFFILIATION WITH EITHER REFERENCE STOCK ISSUER —
We have not independently verified any of the information about either Reference Stock issuer contained in this pricing
supplement. You should undertake your own investigation into each Reference Stock and its issuer. We are not responsible for
either Reference Stock issuer’s public disclosure of information, whether contained in SEC filings or otherwise.
• RISKS ASSOCIATED WITH NON-U.S. COMPANIES WITH RESPECT TO THE ADRs OF NOVO NORDISK A/S —
The ADRs of Novo Nordisk A/S have been issued by a non-U.S. company. Investments in securities linked to the value of such
non-U.S. equity securities involve risks associated with the home countries of the issuers of those non-U.S. equity securities.
•
CURRENCY EXCHANGE RATE RISK WITH RESPECT TO THE ADRs OF NOVO NORDISK A/S —
Because the ADRs of Novo Nordisk A/S are quoted and traded in U.S. dollars on the New York Stock Exchange and the B shares
of Novo Nordisk A/S are quoted and traded in Danish kroner on Nasdaq Copenhagen, fluctuations in the exchange rate between
the Danish krone and the U.S. dollar will likely affect the relative value of the ADRs and the B shares of Novo Nordisk A/S in the
two currencies and, as a result, will likely affect the market price of the ADRs of Novo Nordisk A/S trading on the New York Stock
Exchange. These trading differences and currency exchange rates may affect the market value of the notes and the closing price
of one ADR of Novo Nordisk A/S. The Danish krone has been subject to fluctuations against the U.S. dollar in the past and may be
subject to significant fluctuations in the future. Previous fluctuations or periods of relative stability in the exchange rate between the
Danish krone and the U.S. dollar are not necessarily indicative of fluctuations or periods of relative stability in that rate that may
occur over the term of the notes. The exchange rate between the Danish krone and the U.S. dollar is the result of the supply of,
and the demand for, those currencies. Changes in the exchange rate results over time from the interaction of many factors directly
or indirectly affecting economic and political conditions in Denmark and the United States, including economic and political
developments in other countries. Of particular importance are rates of inflation, interest rate levels, the balance of payments, any
political, civil or military unrest and the extent of governmental surpluses or deficits in Denmark and the United States, all of which
are in turn sensitive to the monetary, fiscal and trade policies pursued by Denmark and the United States and other jurisdictions
important to international trade and finance.

PS-8 | Structured Investments
Uncapped Accelerated Barrier Notes Linked to the Lesser Performing of the
American Depositary Receipts of Novo Nordisk A/S and the Class A
Common Stock of Coupang, Inc.
• THERE ARE IMPORTANT DIFFERENCES BETWEEN THE RIGHTS OF HOLDERS OF THE ADRs OF NOVO NORDISK A/S
AND THE RIGHTS OF HOLDERS OF THE B SHARES OF NOVO NORDISK A/S WITH RESPECT TO THE ADRs OF NOVO
NORDISK A/S —
There are important differences between the rights of holders of the ADRs of Novo Nordisk A/S and the rights of holders of the B
shares of Novo Nordisk A/S, which we refer to as the underlying stock. For example, the issuer of the underlying stock may make
distributions in respect of the underlying stock that are not passed on to the holders of the ADRs of Novo Nordisk A/S. Any such
differences between the rights of holders of the ADRs of Novo Nordisk A/S and the rights of holders of the underlying stock may be
significant and may materially and adversely affect the value of the ADRs of Novo Nordisk A/S and, as a result, the notes.
• LIMITED TRADING HISTORY WITH RESPECT TO THE CLASS A COMMON STOCK OF COUPANG, INC. —
The Class A common stock of Coupang, Inc. commenced trading on the New York Stock Exchange on March 11, 2021 and
therefore has limited historical performance. Accordingly, historical information for that Reference Stock is available only since that
date. Past performance should not be considered indicative of future performance.
• THE ANTI-DILUTION PROTECTION FOR EACH REFERENCE STOCK IS LIMITED AND MAY BE DISCRETIONARY —
The calculation agent will not make an adjustment in response to all events that could affect a Reference Stock. The calculation
agent may make adjustments in response to events that are not described in the accompanying product supplement to account for
any diluting or concentrative effect, but the calculation agent is under no obligation to do so or to consider your interests as a
holder of the notes in making these determinations.

PS-9 | Structured Investments
Uncapped Accelerated Barrier Notes Linked to the Lesser Performing of the
American Depositary Receipts of Novo Nordisk A/S and the Class A
Common Stock of Coupang, Inc.
The Reference Stocks
All information contained herein on the Reference Stocks and on the Reference Stock issuers is derived from publicly available
sources, without independent verification. Each Reference Stock is registered under the Securities Exchange Act of 1934, as
amended, which we refer to as the Exchange Act, and is listed on the exchange provided in the table below, which we refer to as the
relevant exchange for purposes of that Reference Stock in the accompanying product supplement. Information provided to or filed with
the SEC by a Reference Stock issuer pursuant to the Exchange Act can be located by reference to the SEC file number provided in the
table below, and can be accessed through www.sec.gov. We do not make any representation that these publicly available documents
are accurate or complete. We obtained the closing prices below from the Bloomberg Professional® service (“Bloomberg”), without
independent verification.
Reference Stock
Bloomberg
Ticker Symbol
Relevant
Exchange
SEC File
Number
Closing Price on
June 10, 2026
American depositary receipts (“ADRs”), each representing one B
share, nominal value DKK 0.10 each, of Novo Nordisk A/S
NVO
New York Stock
Exchange
333-82318
$42.81
Class A common stock of Coupang, Inc., par value $0.0001 per
share
CPNG
New York Stock
Exchange
001-40115
$15.12
According to publicly available filings of the relevant Reference Stock issuer with the SEC:
• Novo Nordisk A/S, a Danish company, is engaged in the discovery, development, manufacturing and marketing of
pharmaceutical products.
• Coupang, Inc. is a technology company that provides retail, restaurant delivery, video streaming and fintech services to
customers.
Historical Information
The following graphs set forth the historical performance of the ADRs of Novo Nordisk A/S based on the weekly historical closing prices
of one share of that Reference Stock from January 8, 2021 through June 5, 2026 and the historical performance of the Class A
common stock of Coupang, Inc. based on the weekly historical closing prices of one share of that Reference Stock from March 12,
2021 through June 5, 2026. The Class A common stock of Coupang, Inc. commenced trading on the New York Stock Exchange on
March 11, 2021 and therefore has limited historical performance. The closing prices above and below may have been adjusted by
Bloomberg for corporate actions, such as stock splits, public offerings, mergers and acquisitions, spin-offs, delistings and bankruptcy.
The historical closing prices of one share of each Reference Stock should not be taken as an indication of future performance, and no
assurance can be given as to the closing price of one share of either Reference Stock on the Observation Date. There can be no
assurance that the performance of the Reference Stocks will result in the return of any of your principal amount.

PS-10 | Structured Investments
Uncapped Accelerated Barrier Notes Linked to the Lesser Performing of the
American Depositary Receipts of Novo Nordisk A/S and the Class A
Common Stock of Coupang, Inc.
Tax Treatment
You should review carefully the section entitled “United States Federal Taxation” in the accompanying prospectus supplement. The
following discussion, when read in combination with that section, constitutes the full opinion of our special tax counsel, Davis Polk &
Wardwell LLP, regarding the material U.S. federal income tax consequences of owning and disposing of notes.
Based on current market conditions, in the opinion of our special tax counsel it is reasonable to treat the notes as “open transactions”
that are not debt instruments for U.S. federal income tax purposes, as more fully described in “United States Federal Taxation — Tax
Consequences to U.S. Holders — Program Securities Treated as Prepaid Financial Contracts That are Open Transactions” in the
accompanying prospectus supplement. Assuming this treatment is respected, the gain or loss on your notes should be treated as long-
term capital gain or loss if you hold your notes for more than a year, whether or not you are an initial purchaser of notes at the issue
price. However, the IRS or a court may not respect this treatment, in which case the timing and character of any income or loss on the
notes could be materially and adversely affected. In addition, in 2007 Treasury and the IRS released a notice requesting comments on
the U.S. federal income tax treatment of “prepaid forward contracts” and similar instruments. The notice focuses in particular on
whether to require investors in these instruments to accrue income over the term of their investment. It also asks for comments on a
number of related topics, including the character of income or loss with respect to these instruments; the relevance of factors such as
the nature of the underlying property to which the instruments are linked; the degree, if any, to which income (including any mandated
accruals) realized by non-U.S. investors should be subject to withholding tax; and whether these instruments are or should be subject
to the “constructive ownership” regime, which very generally can operate to recharacterize certain long-term capital gain as ordinary
income and impose a notional interest charge. While the notice requests comments on appropriate transition rules and effective dates,
any Treasury regulations or other guidance promulgated after consideration of these issues could materially and adversely affect the
tax consequences of an investment in the notes, possibly with retroactive effect. You should consult your tax adviser regarding the
U.S. federal income tax consequences of an investment in the notes, including possible alternative treatments and the issues presented
by this notice.
Section 871(m) of the Code and Treasury regulations promulgated thereunder (“Section 871(m)”) generally impose a 30% withholding
tax (unless an income tax treaty applies) on dividend equivalents paid or deemed paid to Non-U.S. Holders with respect to certain
financial instruments linked to U.S. equities or indices that include U.S. equities. Section 871(m) provides certain exceptions to this
withholding regime, including for instruments linked to certain broad-based indices that meet requirements set forth in the applicable
Treasury regulations. Additionally, a recent IRS notice excludes from the scope of Section 871(m) instruments issued prior to January
1, 2027 that do not have a delta of one with respect to underlying securities that could pay U.S.-source dividends for U.S. federal
income tax purposes (each an “Underlying Security”). Based on certain determinations made by us, we expect that Section 871(m) will
not apply to the notes with regard to Non-U.S. Holders. Our determination is not binding on the IRS, and the IRS may disagree with
this determination. Section 871(m) is complex and its application may depend on your particular circumstances, including whether you
enter into other transactions with respect to an Underlying Security. If necessary, further information regarding the potential application
of Section 871(m) will be provided in the pricing supplement for the notes. You should consult your tax adviser regarding the potential
application of Section 871(m) to the notes.

PS-11 | Structured Investments
Uncapped Accelerated Barrier Notes Linked to the Lesser Performing of the
American Depositary Receipts of Novo Nordisk A/S and the Class A
Common Stock of Coupang, Inc.
The Estimated Value of the Notes
The estimated value of the notes set forth on the cover of this pricing supplement is equal to the sum of the values of the following
hypothetical components: (1) a fixed-income debt component with the same maturity as the notes, valued using the internal funding
rate described below, and (2) the derivative or derivatives underlying the economic terms of the notes. The estimated value of the
notes does not represent a minimum price at which JPMS would be willing to buy your notes in any secondary market (if any exists) at
any time. The internal funding rate used in the determination of the estimated value of the notes may differ from the market-implied
funding rate for vanilla fixed income instruments of a similar maturity issued by JPMorgan Chase & Co. or its affiliates. Any difference
may be based on, among other things, our and our affiliates’ view of the funding value of the notes as well as the higher issuance,
operational and ongoing liability management costs of the notes in comparison to those costs for the conventional fixed income
instruments of JPMorgan Chase & Co. This internal funding rate is based on certain market inputs and assumptions, which may prove
to be incorrect, and is intended to approximate the prevailing market replacement funding rate for the notes. The use of an internal
funding rate and any potential changes to that rate may have an adverse effect on the terms of the notes and any secondary market
prices of the notes. For additional information, see “Selected Risk Considerations — Risks Relating to the Estimated Value and
Secondary Market Prices of the Notes — The Estimated Value of the Notes Is Derived by Reference to an Internal Funding Rate” in this
pricing supplement.
The value of the derivative or derivatives underlying the economic terms of the notes is derived from internal pricing models of our
affiliates. These models are dependent on inputs such as the traded market prices of comparable derivative instruments and on
various other inputs, some of which are market-observable, and which can include volatility, dividend rates, interest rates and other
factors, as well as assumptions about future market events and/or environments. Accordingly, the estimated value of the notes is
determined when the terms of the notes are set based on market conditions and other relevant factors and assumptions existing at that
time.
The estimated value of the notes does not represent future values of the notes and may differ from others’ estimates. Different pricing
models and assumptions could provide valuations for the notes that are greater than or less than the estimated value of the notes. In
addition, market conditions and other relevant factors in the future may change, and any assumptions may prove to be incorrect. On
future dates, the value of the notes could change significantly based on, among other things, changes in market conditions, our or
JPMorgan Chase & Co.’s creditworthiness, interest rate movements and other relevant factors, which may impact the price, if any, at
which JPMS would be willing to buy notes from you in secondary market transactions.
The estimated value of the notes will be lower than the original issue price of the notes because costs associated with selling,
structuring and hedging the notes are included in the original issue price of the notes. These costs include the selling commissions, if
any, paid to JPMS and other affiliated or unaffiliated dealers, the projected profits, if any, that our affiliates expect to realize for
assuming risks inherent in hedging our obligations under the notes, the estimated cost of hedging our obligations under the notes and
the fees, if any, paid for third-party data analytics and/or electronic platform services. Because hedging our obligations entails risk and
may be influenced by market forces beyond our control, this hedging may result in a profit that is more or less than expected, or it may
result in a loss. A portion of the profits, if any, realized in hedging our obligations under the notes sold to brokerage accounts may be
allowed to other affiliated or unaffiliated dealers, and we or one or more of our affiliates will retain any remaining hedging profits. See
“Selected Risk Considerations — Risks Relating to the Estimated Value and Secondary Market Prices of the Notes — The Estimated
Value of the Notes Will Be Lower Than the Original Issue Price (Price to Public) of the Notes” in this pricing supplement.
Secondary Market Prices of the Notes
For information about factors that will impact any secondary market prices of the notes, see “Risk Factors — Risks Relating to the
Estimated Value and Secondary Market Prices of the Notes — Secondary market prices of the notes will be impacted by many
economic and market factors” in the accompanying product supplement. In addition, we generally expect that some of the costs
included in the original issue price of the notes will be partially paid back to you in connection with any repurchases of your notes by
JPMS in an amount that will decline to zero over an initial predetermined period. These costs can include selling commissions, if any,
projected hedging profits, if any, and, in some circumstances, estimated hedging costs, our internal secondary market funding rates for
structured debt issuances and the fees paid for third-party data analytics and/or electronic platform services. This initial predetermined
time period is intended to be the shorter of six months and one-half of the stated term of the notes. The length of any such initial period
reflects the structure of the notes, whether our affiliates expect to earn a profit in connection with our hedging activities, the estimated
costs of hedging the notes and when these costs are incurred, as determined by our affiliates. See “Selected Risk Considerations —
Risks Relating to the Estimated Value and Secondary Market Prices of the Notes — The Value of the Notes as Published by JPMS
(and Which May Be Reflected on Customer Account Statements) May Be Higher Than the Then-Current Estimated Value of the Notes
for a Limited Time Period” in this pricing supplement.

PS-12 | Structured Investments
Uncapped Accelerated Barrier Notes Linked to the Lesser Performing of the
American Depositary Receipts of Novo Nordisk A/S and the Class A
Common Stock of Coupang, Inc.
Supplemental Use of Proceeds
The notes are offered to meet investor demand for products that reflect the risk-return profile and market exposure provided by the
notes. See “Hypothetical Payout Profile” and “How the Notes Work” in this pricing supplement for an illustration of the risk-return profile
of the notes and “The Reference Stocks” in this pricing supplement for a description of the market exposure provided by the notes.
The original issue price of the notes is equal to the estimated value of the notes plus the selling commissions, if any, paid to JPMS and
other affiliated or unaffiliated dealers, plus (minus) the projected profits (losses) that our affiliates expect to realize for assuming risks
inherent in hedging our obligations under the notes, plus the estimated cost of hedging our obligations under the notes, plus the fees, if
any, paid for third-party data analytics and/or electronic platform services.
Supplemental Plan of Distribution
With respect to notes sold to certain fee-based advisory accounts for which an affiliated or unaffiliated broker-dealer is an investment
adviser, the price to the public will not be lower than $971.50 per $1,000 principal amount note. JPMS and these broker-dealers will
forgo any selling commissions related to these sales. See “Plan of Distribution (Conflicts of Interest)” in the accompanying product
supplement.
With respect to notes sold to brokerage accounts, JPMS, acting as agent for JPMorgan Financial, will pay all of the selling commissions
it receives from us to other affiliated or unaffiliated dealers. In no event will these selling commissions exceed $28.50 per $1,000
principal amount note. See “Plan of Distribution (Conflicts of Interest)” in the accompanying product supplement.
Additional Terms Specific to the Notes
You may revoke your offer to purchase the notes at any time prior to the time at which we accept such offer by notifying the applicable
agent. We reserve the right to change the terms of, or reject any offer to purchase, the notes prior to their issuance. In the event of any
changes to the terms of the notes, we will notify you and you will be asked to accept such changes in connection with your purchase.
You may also choose to reject such changes, in which case we may reject your offer to purchase.
You should read this pricing supplement together with the accompanying prospectus, as supplemented by the accompanying
prospectus supplement relating to our Series A medium-term notes of which these notes are a part, and the more detailed information
contained in the accompanying product supplement. This pricing supplement, together with the documents listed below, contains the
terms of the notes and supersedes all other prior or contemporaneous oral statements as well as any other written materials including
preliminary or indicative pricing terms, correspondence, trade ideas, structures for implementation, sample structures, fact sheets,
brochures or other educational materials of ours. You should carefully consider, among other things, the matters set forth in the “Risk
Factors” sections of the accompanying prospectus supplement and the accompanying product supplement, as the notes involve risks
not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisers
before you invest in the notes.
You may access these documents on the SEC website at www.sec.gov as follows (or if such address has changed, by
reviewing our filings for the relevant date on the SEC website):
• Product supplement no. 3-I dated April 17, 2026:
http://www.sec.gov/Archives/edgar/data/19617/000121390026045198/ea0285802-20_424b2.pdf
• Prospectus supplement and prospectus, each dated April 17, 2026:
http://www.sec.gov/Archives/edgar/data/19617/000095010326005889/crt_dp245141-424b2.pdf
Our Central Index Key, or CIK, on the SEC website is 1665650, and JPMorgan Chase & Co.’s CIK is 19617. As used in this pricing
supplement, “we,” “us” and “our” refer to JPMorgan Financial.